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Abstract: The cerebral endothelium is an active interface between blood and the central nervous
system. In addition to being a physical barrier between the blood and the brain, the endothelium
also actively regulates metabolic homeostasis, vascular tone and permeability, coagulation, and
movement of immune cells. Being part of the blood–brain barrier, endothelial cells of the brain
have specialized morphology, physiology, and phenotypes due to their unique microenvironment.
Known cardiovascular risk factors facilitate cerebral endothelial dysfunction, leading to impaired
vasodilation, an aggravated inflammatory response, as well as increased oxidative stress and vascular
proliferation. This culminates in the thrombo-inflammatory response, an underlying cause of ischemic
stroke and cerebral small vessel disease (CSVD). These events are further exacerbated when blood
flow is returned to the brain after a period of ischemia, a phenomenon termed ischemia-reperfusion
injury. Purinergic signaling is an endogenous molecular pathway in which the enzymes CD39 and
CD73 catabolize extracellular adenosine triphosphate (eATP) to adenosine. After ischemia and CSVD,
eATP is released from dying neurons as a damage molecule, triggering thrombosis and inflammation.
In contrast, adenosine is anti-thrombotic, protects against oxidative stress, and suppresses the
immune response. Evidently, therapies that promote adenosine generation or boost CD39 activity at
the site of endothelial injury have promising benefits in the context of atherothrombotic stroke and
can be extended to current CSVD known pathomechanisms. Here, we have reviewed the rationale
and benefits of CD39 and CD39 therapies to treat endothelial dysfunction in the brain.
Keywords: CD39; endothelial dysfunction; brain; stroke; endothelial cells; purinergic signaling
1. Introduction
The endothelium is a monolayer of cells that is able to respond to physical and chemi-
cal signals by the production of a wide range of factors that regulate vascular tone, cellular
adhesion, thromboresistance, smooth muscle cell proliferation, and vessel wall inflamma-
tion [1]. It also acts as a signal transduction interface to generate appropriate vasomotor
signals such as ion channel activation, biochemical, and transcriptional events [2].
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The endothelium shows large phenotypic heterogeneity in different vascular sections
and organs including variations in morphology, behavior, and biosynthetic repertoire [3]
due to differing needs specific to the local environment. Most organs such as the brain as
well as the blood vessels of the circulatory system show a continuous endothelial monolayer
with a well-expressed continuous basement membrane consisting of matrix components
such as laminin, fibronectin, vinculin, and collagen expressed by endothelial cells during
vascular growth [2].
The vasculature of the brain is made up of a large network of small and large vessels,
the entirety of which is lined with endothelial cells (ECs). Brain capillary ECs lack fen-
estrations, are interspersed by tight junctions, and have reduced pinocytotic activity [4].
Additionally, the endothelium of the cerebral vessels serves a special function: they are a
critical structural component of the neurovascular unit that constitutes the blood–brain
barrier (BBB). It is the primary barrier between systemic circulation and the brain, and it
regulates the transportation of solutes between the blood and brain [5]. The cerebral vascu-
lar endothelium has an overall prothrombotic-antifibrinolytic environment characterized
by reduced levels of both thrombomodulin and tissue plasminogen activator (tPA) and
high levels of plasminogen activator inhibitor-1 (PAI-1) [4].
This review aims to discuss endothelial dysfunction as the underlying cause for
ischemic stroke and CSVD, and to expand on the cytoprotective potential of the purinergic
signaling pathway in these conditions.
2. Endothelial Dysfunction
The endothelium has a key role in the production and release of nitric oxide (NO),
which is produced from arginine by eNOS (endothelial nitric oxide synthase). NO relaxes
smooth muscle cells, thereby preventing leukocyte adhesion and migration into the arterial
wall. NO also curbs muscle cell proliferation, platelet adhesion and aggregation, and
expression of adhesion molecules such as vascular cell adhesion molecule (VCAM) and
intercellular cell adhesion molecule (ICAM). Known cardiovascular risk factors like aging,
smoking, diabetes, hypertension, and high homocysteine or cholesterol levels cause struc-
tural and functional disturbances to the endothelium, leading to endothelial dysfunction.
This occurs due to NO bioavailability being limited either by reduced eNOS production
or by increased release of reactive oxygen species (ROS). Together with impaired NO
production and altered vasodilatation, damaged endothelial cells secrete vasoconstrictors
including endothelin-1, thromboxane A2, prostaglandin H2, and promote more ROS re-
lease. Endothelial dysfunction also initiates inflammation and apoptosis of endothelial
cells and adjacent cells in the vessel wall [6].
Emerging Role of Erythrocytes in Endothelial Dysfunction
Red blood cells also play a role in endothelial dysfunction, though is largely under
researched. The biconcave shape of erythrocytes is of great physiological significance as it
confers a larger surface area relative to volume and is important for an effective gaseous
exchange. Furthermore, this allows the drastic shape change that erythrocytes need to
undergo while traversing through capillaries [7]. The diameter of the capillaries that
erythrocytes need to traverse are often smaller than the diameter of the erythrocyte (7 µm)
itself. In such cases, erythrocytes deform to take a parachute-like shape, which facilitates
their transit across capillaries, a phenomenon known as erythrocyte deformability. Reactive
oxygen species (ROS) release during ischemia damages the membranes of erythrocytes,
resulting in increased fragility and reduced maturation and erythrocyte distribution width,
which decreases erythrocyte deformability. Rigid erythrocytes tend to aggregate [8], which
increases whole blood viscosity [9] and underlies vessel wall shear stress. Shear stress is
a mechanical force acting directly on ECs, and disturbances in mechanical forces on ECs
affect the NO-synthesizing mechanisms in the vascular endothelium [10]. Thus, erythrocyte
deformability is an important determining factor for normal microcirculation. Decreased
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erythrocyte deformability causes microcirculation sludging as it is difficult for a rigid
erythrocyte to squeeze in through the capillaries [11,12].
Microcirculation sludging also induces endothelial dysfunction as it increases the in-
teraction of blood cells and plasma constituents with the endothelium [13]. The interaction
of rigid, aggregated, and hyper-viscous erythrocytes with the capillary endothelium results
in structural and biochemical changes, altering the microvascular integrity [14–16], which
further promotes endothelial dysfunction [17,18]. Indeed, microscopic analysis has shown
focal endothelial swelling and loss of pinocytic vessels in the affected cells [19]. In addition,
microcirculation sludging decreases wall shear stress in the endothelium and downreg-
ulates the NO-dependent flow mediated vasodilation [10,20,21]. An observation in a rat
model of erythrocyte aggregation showed blunted flow mediated dilation and suppressed
endothelial NO synthesis mechanism [10]. Decreased erythrocyte deformability may also
induce endothelial dysfunction by decreasing bioactive endogenously synthesized NO [22].
A reduced concentration of NO promotes vasoconstriction, platelet aggregation, smooth
muscle cell proliferation and migration, leukocyte adhesion, oxidative stress, and systemic
inflammation [23,24], all leading to thrombosis.
Microcirculation sludging beyond a certain threshold triggers thrombotic events [25].
Erythrocytes can contribute to thrombin generation independent of platelets and leuko-
cytes [26,27]. This was attributed to the presence of an exposed phosphatidyl serine
(negatively charged phospholipid, normally on the cytoplasmic side of the membrane)
on a very small number (0.51%) of the erythrocyte population even under physiological
conditions. The thrombin generation potential of erythrocytes is linearly increased cor-
responding to the increase in hematocrit [28]. Microcirculation sludging increases local
hematocrit, which creates a favorable environment for thrombin generation. Reduced
blood flow due to an experimental increase in erythrocyte aggregation and whole blood vis-
cosity has been shown to rapidly create thrombosis (within 30 min) at the site of endothelial
injury in rabbit femoral veins [29]. Erythrocytes also adhere to the endothelium through
adhesion molecules such as VCAM-1, and such adhesion is associated with a higher risk of
thrombosis and vascular complications [30]. In summary, altered hemorheology (i.e., de-
creased erythrocyte deformability, increased erythrocyte aggregation, and increased whole
blood viscosity) increases the capillaries’ flow resistance and microcirculation sludging,
causing endothelial dysfunction [31,32]. Indeed, altered hemorheology is an independent
risk factor of primary and secondary stroke and may contribute to stroke pathogenesis.
3. Thrombo-Inflammation in Atherothrombotic Stroke
The brain has high energy demand and accounts for ~20% of total oxygen consump-
tion, which makes it highly susceptible to oxidative stress [4]. The endothelium is the
regulator of hemostasis in the brain [33,34] and oxidative stress causes endothelial acti-
vation leading to a pro-thrombotic and pro-inflammatory phenotype and a loss of BBB
integrity. Changes to the vascular structure and mechanics also contribute to endothelial
dysfunction [34], for example, degeneration of vascular wall and loss of BBB integrity
promotes movement of molecules out of circulation, and into the parenchyma [35,36].
Endothelial dysfunction affecting cerebral blood flow is a significant underlying cause
of both ischemic stroke and CSVD. Ischemic stroke occurs either due to large vessel arterial
thrombi or due to cerebrovascular complications affecting both large and small blood
vessels of the brain. CSVD is characterized by microvascular changes, resulting in small
regions of ischemia and microbleeds (microhemorrhages) [4].
3.1. Cerebral Ischemia Leading to Stroke
Acute ischemic stroke (AIS), accounting for approximately 85% of stroke episodes [37],
results from transient or permanent reduction in cerebral blood flow (cBF) of a major brain
artery [38,39]. This event is caused by an occlusion of a cerebral artery due to thrombosis or
an embolism, which stems from underlying endothelial dysfunction [37,38]. It is important
Biomolecules 2021, 11, 994 4 of 15
to understand this complex and damaging neurological condition, as stroke is the leading
cause of death and acquired disability worldwide [37,40].
Mechanism of Endothelial Dysfunction in Ischemic Stroke
Endothelial dysfunction largely underpins the pathogenesis of ischemic stroke. In
response to ischemia and its subsequent hypoxic state, there is a severe restriction of
oxygen and glucose delivered to the brain [38,39]. The lack of blood flow also causes in-
creased edema via intracellular Ca2+ excess [38,41]. Further, ischemia impairs endothelium-
dependent vasodilation, which limits reperfusion of blood flow [34]. Impaired endothelium-
dependent vasodilation of cerebral blood vessels is associated with several key risk factors
for stroke such as chronic hypertension, diabetes, and hypercholesterolemia [42].
Impairment of endothelial nitric oxide synthase (eNOS) is also implicated in ischemia-
induced endothelial dysfunction. Lack of eNOS activity leads to sharp increases of ROS due
to impaired NO generation [43]. Increased generation of ROS by the damaged endothelium
and subsequent hypoxia triggers pro-inflammatory gene activation to activate microglia
and astrocytes, and causes an influx of inflammatory cells [38,44,45] recruited by cytokines,
adhesion molecules, and chemokines [37]. The endothelium is further dysregulated due to
the influx of inflammatory cells into the brain parenchyma. Ischemic stroke induces a strong
inflammatory response that begins as soon as a few hours of initial onset, and it especially
characterizes the delayed response to ischemia [37]. Ischemic inflammatory damage to
the brain involves the infiltration of neutrophils that cause microvascular obstruction,
and worsens ischemic injury and endothelial dysfunction [46], and the production of
toxic mediators by activated inflammatory cells and injured neurons (i.e., cytokines, NO,
superoxides) that can amplify endothelial damage [38,41]. Furthermore, neutrophil stalling
of brain capillaries contributes to reperfusion failure [47] (Figure 1).
In cerebral ischemia, the accumulation of ROS and impairment of eNOS generation
propagates a pro-inflammatory and pro-oxidant environment [43]. This potentiates throm-
bus formation and further increases in proinflammatory cytokines [i.e., interleukins (IL-6
and IL-8, TNF-α, and monocyte chemoattractant protein 1 (MCP-1)], and expression of
vascular adhesion molecules triggering endothelial dysfunction [48].
BBB disruption and edema is also a key contributor of endothelial dysfunction [38,41],
where damage to the brain causes an activation of inflammatory response initiated by
neutrophil infiltration through the BBB [38,44,45]. Reperfusion is denoted by the reestab-
lishment of blood flow to the ischemic area, and though reperfusion is necessary for tissue
survival, it contributes significantly to additional tissue damage and vessel permeability,
which is termed ischemia-reperfusion injury. Increased neutrophil infiltration has been
shown to correspond to the biphasic permeability of the BBB [49] and initial reperfusion can
also account for the loss of cerebral autoregulation and reactive hyperemia. Following the
initial hyperemia, hypoperfusion of the ischemic area occurs, which can enhance neutrophil
adhesion, oxidative stress, and subsequent inflammatory activity, and directly contributes
to the subsequent vessel permeability [50].
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endfeet projecting onto the basement membrane. Endothelial dysfunction and BBB disruption causes astrocytes to detach 
from the BBB. Inflammation also causes the disruption of cell–cell interactions and degradation of the basement mem-
brane, which exacerbates cell injury. This leads to a narrowing of the lumen and subsequent reduction in cerebral blood 
flow (CBF). This increases the probability of hypoxia and injury to neuronal cells and the parenchyma. Ischemic stroke: 
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Figure 1. Endothelial dysfunction underlies the pathophysiology of CSVD and ischemic stroke. CSVD: Cardiovascular risk
factors of atherosclerosis, diabetes, and/or aging, trigger endothelial activation and subsequent endothelial dysfunction
by promoting a pro-oxidant and pro-inflammatory environment. This in turn leads to the release of cytokines and
endothelial microparticles, which further promote endothelial injury. Oxidative stress dysregulates endothelial nitric oxide
synthase (eNOS) production, which leads to reduced nitric oxide (NO) bioavailability and impaired endothelial vasodilatory
responses. Microthrombi may be formed on the endothelial surface. Endothelial disruption leads to loss of blood–brain
barrier (BBB) integrity and tight junction damage, causing microvascular bleeding. The BBB is comprised of endothelial
cells strengthened by tight junctions on the luminal side and a basement membrane with pericytes and astrocyte endfeet
projecting onto the basement membrane. Endothelial dysfunction and BBB disruption causes astrocytes to detach from the
BBB. Inflammation also causes the disruption of cell–cell interactions and degradation of the basement membrane, which
exacerbates cell injury. This leads to a narrowing of the lumen and subsequent reduction in cerebral blood flow (CBF). This
increases the probability of hypoxia and injury to neuronal cells and the parenchyma. Ischemic stroke: Occurs due to an
occlusion in the cerebral blood vessels, which restricts blood flow in the brain. The occlusion is commonly caused by the
formation of a thrombus after damage o the endoth lium. Damage to cells causes the release f ATP nd upregulation f
vWF on the endothelium. ATP is conv rted to ADP, leading t platelet activation nd aggregation to the site of injury, thus
forming a thrombus. This triggers several downstream processes, which further dysregulates the endothelium. The lack of
blood flow leads to immediate energy failure and excitotoxicity, which leads to an increase in intracellular Ca2+ and Na+.
Increases in intracellular Ca2+ directly increase mitochondrial permeability and induce the expression of cytochrome C,
phospholipase A2, and cyclooxygenase, which cause membrane degradation and the increase of free radicals and reactive
oxygen species (ROS), leading to oxidative stress. ROS causes DNA damage and the increase of inflammatory mediators
such as cytokines (TNFα, IL-1β), adhesion molecules (VCAM-1, ICAM-1), and chemokines (IL-8, MCP-1), which in turn
leads to increased leukocyte infiltration and microglial activation, causing widespread inflammation and apoptosis. The
increased intr cellul r Na+ leads to peri-infarct depolariz ti n and the increas of extracellular glutamate and K+ as well as
BBB damage and vasogenic oedema (created with BioRender.com).
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3.2. Cerebral Small Vessel Disease (CSVD)
CSVD of the brain parenchyma represents a spectrum of clinical and neuropathologi-
cal processes with various etiologies involving the cerebral microvasculature (50–400 µm
in diameter) that penetrates and supplies the brain subcortical region [51,52]. This mi-
crocirculation network includes small penetrating arteries (chiefly middle cerebral artery
tributaries), arterioles, capillaries, small veins, and venules. With increasing prevalence
amongst older people, CSVD is a significant precursor for dementia and stroke. Manifest-
ing as lacunar infarcts, microbleeds, enlarged perivascular spaces, and cortical atrophy,
CSVD accounts for almost 45% of the total global cases of dementias, 25% of ischemic
strokes, and over 70% of vascular dementia [53,54]. Given the neuroimaging identification
of several manifestations of CSVD, varying degree of prevalence and health burden have
been reported in both healthy and diseased populations [55–57].
Evolving Pathomechanism of CSVD
It is recognized that most of the macrostructural manifestations in CSVD as detected
from neuroimaging are likely to be the end-result of the underlying mesostructural re-
sponses such as cerebral microcirculation flow obstruction (either from intrinsic or extrinsic
causes). In this instance, the arteriolar occlusion or narrowing results in a symptomatic
ischemic event as seen in small lacunar infarcts in the classical CSVD spectrum. Axonal
injury, neuronal apoptosis, demyelination, and oligodendrocyte damage also occur during
CSVD, leading to cerebral parenchyma damages, which may manifest as neurological
symptoms, clinical signs, and multifaceted neuroimaging findings including silent brain
infarct [58]. The pathomechanism of sporadic CSVD also encompasses systemic dysregula-
tions, which include coagulopathy, elevated microvascular thrombosis, increased cellular
activation, inflammation, and oxidative stress. These processes influence the underlying
cerebral microstructural changes known to occur in CSVD (i.e., endothelial dysfunction,
altered cBF, and breakdown of the BBB, Figure 1).
4. Involvements of Purinergic Signaling
4.1. Purinergic Signaling
Purinergic signaling is the collective term to describe how purine nucleotides function
as extracellular signaling molecules. The adenosine-signaling pathway constitutes adeno-
sine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP),
and adenosine, which modulate a range of functions such as EC growth and apoptosis,
coagulation, vessel tone, and inflammation. ATP is hydrolyzed into ADP and subsequently
into AMP by ectonucleotidase CD39; AMP is then converted into adenosine by CD73,
which is ubiquitously expressed (Figure 2). Purinergic signaling is involved in the regula-
tion of the immune responses [59]; ATP release in response to inflammatory mediators was
found to be a basic mechanism required for neutrophil activation and immune defense [60].
The receptors P1 and P2 expressed on the surface of immune cells are activated by adeno-
sine and ATP, respectively, and mediate the immunomodulatory effects of purines. Four G
protein-coupled P1 or adenosine receptors have been identified as A1, A2A, A2B, and A3,
whereas the P2 receptors have been classified into two subfamilies: the ionotropic P2X (P2
× 1–7) and metabotropic P2Y (P2Y1,2,4,6,11–14) receptors [61,62].
Cellular ATP is the main energy source of the body that drives virtually all cell func-
tions. Intracellular ATP is involved in energy transport and pathophysiological roles, while
extracellular ATP (eATP) serves as a multifunctional intercellular signaling system and
is ubiquitously used for cell–cell communication [63]. Not only is eATP actively secreted
through plasma membrane proteins such as pannexin and connexin, it is also passively
released after stress induced cell injury [64]. Particularly, eATP levels are increased during
times of tissue stress, for example, during necrosis, apoptosis, hypoxia, or inflammation [65]
and acts as danger-associated molecular pattern signals (DAMP) to bind to purinergic
receptors and to induce an inflammatory signaling cascade [61,66]. ATP is present in high
concentrations in the brain [67] due to large energy requirements. ATP concentrations can
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rise due to vesicular release from neurons, exocytosis from astrocytes and microglia, or
through membrane channels from glial cells and pyramidal neurons [68]. During ischemia-
hypoxia, eATP and adenosine increase drastically due to glutamate accumulation from
ion pump failure [37,38], exocytosis from microglia [69], and astrocytes [70], among other
reasons. This excessive production of eATP and adenosine is high enough to stimulate
all nearby P1 and P2 receptors [71], which are present at significant levels in neurons
and most peripheral inflammatory cells [68]. This in turn induces a pro-inflammatory
environment. In fact, eATP itself aggravates cerebral damage after ischemic stroke as high
ATP concentrations induce cell death [72].
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Figure 2. The role of the purinergic signaling pathway in regulating endothelial function. Hypoxia, thrombosis, and
ischemia-reperfusion injury promote extracellular ATP (eATP) release from dying astrocytes and neurons that potentiates
endothelial dysfunction. Damaged endothelial cells release pro-inflammatory factors such as TNF-α, which directly upregu-
late leukocyte-endothelial adhesion molecules (VCAM-1, ICAM-1) to facilitate leukocyte adherence and transmigration
through the endothelium. This contributes to a pro-inflammatory and pro-oxidative environme t. CD39 is expressed
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ADP is a platelet agonist that functions in physiological hemostasis and thrombo-
sis [73]. It is an important mediato of platelet activation induced by other activators s ch
as thrombin and collagen, which in tur , creates a positive fee back l op pr moting ADP
release from intr platelet storage pools, thereby enhancing platelet aggre atio and he
proliferation of a platel t plug [73] during inj ry.
Aden sine, which is produced by the breakdown of ATP, is key e dogenous molecule
that regulates tissue functio [74] and acts as a endogeno s neuroprotectant [68]. Specifi-
cally, it triggers IL-10 production [75], which suppresses cytokine secretion, antigen presen
tation, and CD4+ T cell activation [76]. Adenosin accumulates in the extracellular space in
response to metab lic stress a cell damage, and h poxia, schemi , and inflammation all
stimulate local ad osine productions [74]. The rapid eleas of adenosine i response to
noxious stimuli has a dual role in modul ting homeostasis. First, it reports tissue injury in
an autocrine and paracrine an er to surrounding tissue, and it generates organ protective
tissue responses, thereby restoring homeostasis [77]. Extracellular adenosine dampens
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hypoxia-induced inflammation [78] and pharmacologically increasing the breakdown of
ATP to adenosine is effective in attenuating tissue injury and sterile inflammation during
ischemia-reperfusion injury [79–85]. Adenosine also has an important function in sup-
pressing the immune response, inhibits T-cell activation, and adenosine receptors (A2A
receptors) are found on CD4+ T cells [86].
4.2. Role of Endothelial CD39 in Preventing Thrombo-Inflammation
CD39 is an ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) expressed
by endothelial cells in the vasculature. Its primary action is to convert ATP/ADP into
AMP, and subsequently CD73 converts AMP into adenosine (Figure 2). CD39 is liberated
from the coronary vascular endothelium by ischemia-reperfusion, and levels of circulating
ectonucleotidase may reflect the severity of ischemic vascular injury [87]. Attenuation or
lack of CD39 activity is associated with vascular dysfunction and remodeling in pulmonary
arterial hypertension [88] and failure of vascular reconstitution [89].
CD39/CD73 regulates the vascular environment by converting the pro-thrombotic and
pro-inflammatory ATP and ADP rich environment into an antithrombotic anti-inflammatory
adenosine rich state [65] through platelet aggregation, tissue factor expression suppression,
and anti-inflammatory mediation [90–92].
CD39 has an integral role in normal hemostasis, and regulates prothrombotic and
proinflammatory responses [93]. Expression of CD39 is a key determinant of occlusive
thrombus formation and therapies that promote CD39 expression are likely to increase
antithrombotic efficacy. Global overexpression of human CD39 yields profound antithrom-
botic effects [94–96], though its effect may in part be due to the reduction of ADP-induced
platelet activation [97,98]. CD39 is also important in leukocyte trafficking across the
endothelium in response to chemokines and regulates immune cell adhesion to the en-
dothelial layer where cell adhesion is promoted by the ATP rich environment and inhibited
by adenosine [99]. CD39−/− mice display increased leukocyte adhesion as well as impaired
adenosine generation, resulting in increased EC activation, greater monocyte recruitment,
platelet aggregation, and increased endothelial permeability [92,100–102].
4.3. Involvement of Adenosine as Potential Innate Neuroprotection
Adenosine has an important role in the brain’s response to an ischemic event. Stud-
ies have demonstrated that the extracellular adenosine concentration levels in the brain
increase within the first 20 min after ischemia and return to basal after 4 h [71]. This
initial burst of adenosine may represent a critical biological protective feature of the brain
following a stroke. Pignataro et al. showed an increase in infarct volume after transient
middle cerebral artery occlusion [103] in transgenic mice that had low levels of adenosine
due to overexpression of adenosine kinase, a main metabolic enzyme of adenosine [104].
In humans, an increase in circulating plasma adenosine levels, peaking on day 2 for
transient ischemic attack and day 3 for stroke [105], further supports the role of adenosine
as an endogenous innate self-repair neuroprotective mechanism. Its role in modulating sys-
temic immune responses after stroke is also noteworthy [106]. The peripheral immune cells
express adenosine receptors and respond to changes in extracellular adenosine. Adenosine
modulates the activity of immune cells differentially depending on the receptors that
are activated. For instance, the activation of A2A and A2B receptors stimulates an anti-
inflammatory response by the peripheral immune cells. This property could potentially
be exploited to reduce inflammatory damage in the CNS caused by infiltrating activated
immune cells after stroke. In the other hand, the activation of A1 receptors on immune
cells promotes migration and phagocytic activity [107] as well as angiogenesis through
their interaction with vascular ECs [108].
Logically, pharmacological agents that modify local concentration of ATP and adeno-
sine have been explored as a protective strategy after stroke. Therapies promoting adeno-
sine generation are beneficial in animal models of stroke but have not been successful
clinically. Adenosine is neuroprotective; administration of adenosine reduces both stroke-
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related brain damage and hypoxic–ischemic neuronal injury. Indeed, Kitagawa et al.
showed that exogenous adenosine infusion into the ipsilateral striatum (immediately after
occlusion, and continued until 3 h after reperfusion) significantly reduced infarct volume
and improved neurological outcome after transient middle cerebral artery occlusion [103].
However, controlled, targeted delivery of adenosine to the central nervous system is not
feasible as its half-life in human plasma is <5 s. Adenosine receptor agonists overcome this
issue but can only be delivered at early timepoints after ischemia as delayed administration
is associated with systemic off-target effects [68].
One therapeutic approach is to enhance hydrolysis of eATP by upregulation of nu-
cleoside triphosphate diphosphohydrolases (NTPDases) and ecto-5′-nucleotidase, thus
inducing adenosine formation. A few of the more promising therapies include Activin
A, APT102, and HMG-CoA reductase inhibitors. Activin A is a pleiotropic cytokine used
to upregulate the expression of CD39, and to stimulate CD39 related anti-inflammatory
processes. Mukerji et al. demonstrated that intracerebroventricular administration of
Activin A exerted neuroprotective effects including reduced infarct volume and improved
neurological outcomes in experimental stroke. Activin A treatment attenuated neuronal
apoptosis pathways as well as microglial activation [109]. A follow up study by Buchthal
et al. demonstrated that intranasal administration of Activin A reduced infarct volume [110]
after stroke. Another promising molecule is APT102, a recombinant form of CD39 hu-
man apyrase. Tan et al. demonstrated that the combination of r-tPA (tissue plasminogen
activator) and APT102 reduces mortality rate, decreases infarct volume, and improves
neurological deficit scores as well as prevents r-tPA-induced hemorrhage transformation in
the experimental stroke model [111]. An advantage is that APT102 does not act directly on
platelets but has an antithrombotic effect as a result of hydrolyzing eADP and inhibiting
platelet aggregation with a minimally elevated risk for bleeding. Interestingly, statin (or
HMG-CoA reductase inhibitors), commonly used cholesterol-lowering drugs, have been
shown to increase endothelial CD39 expression [112] and reduce thrombin-induced platelet
aggregation [113], suggesting antithrombotic and anti-inflammatory effects on vascular
cells. Two meta-analyses have shown that statin therapy at stroke onset is associated with
good functional outcome in patients with ischemic stroke [114,115]. Nevertheless, therapies
that target adenosine generation should be viewed with caution due to the widespread
distribution of adenosine receptors within the brain. Furthermore, the optimal window of
administration for adenosine-modulating drugs is critical as the complex pathophysiologi-
cal processes following stroke are influenced differentially by adenosine both spatially and
temporally.
5. Therapeutic Potential of CD39
CD39 and CD73 are the principal enzymes involved in endogenous adenosine gen-
eration. Initial studies based on CD39 knockout mice and pharmacological inhibition of
CD39 both showed that it is a crucial enzyme for protecting against increased vascular
permeability and neutrophil extravasation during local hypoxia [101,116,117]. In CD39
knockout mice, cerebral [92,102], cardiac [85,118], renal [81,119], and intestinal [83] injuries
were more severe than wildtype littermate controls. Pharmacological adenosine receptor
agonists, or administration of soluble CD39 before the induction of ischemic insult induced
a protective effect in the wild-type and the knockout mice. Pinsky et al. showed that
CD39 knockout mice exhibited increased cerebral infarct volumes, and decreased post
ischemic perfusion, and exogenous addition of soluble recombinant CD39 was able to
reduce thrombosis, increase post-ischemic perfusion, and decrease cerebral infarct volumes
in vivo even when given 3 h post-stroke. They also observed that the exogenous addition
of CD39 did not cause any bleeding complications [102].
The protective role of CD39 has also been validated using transgenic mice that over-
express CD39. In a mouse cardiac transplant model of vascular rejection, it was shown
that the transgenic mice were also substantially protected from thrombosis and survived
longer post-transplant [120]. We showed that overexpression conferred protection in a
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murine model of warm renal ischemia reperfusion injury, and in a murine model of liver
transplantation [121,122]. Interestingly, the beneficial effect did not seem to be due to
elevated levels of CD39 in the liver, but rather by a CD39-mediated reduction in CD4+ cells
in the donor liver [121], confirming that CD39-mediated adenosine generation is important
in regulating the immune response following ischemia-reperfusion injury.
The therapeutic potential of CD39 in the ischemic brain was explored by Baek et al. [123],
who developed a transgenic mouse overexpressing human CD39 either globally or in
myeloid-lineage cells only. They found that the transgenic CD39 mice had decreased
recruitment of macrophages and neutrophils, and overall decreased inflammation in the
ischemic hemispheres. These mice also exhibited reduced neurological deficit and smaller
infarct volumes, suggesting an overall therapeutic benefit of CD39 in stroke [123].
Previous work has demonstrated that in other CD39 transgenic mice, there was no
overt spontaneous bleeding tendencies under normal circumstances. However, they did
exhibit impaired platelet aggregation, prolonged bleeding times, and resistance to systemic
thromboembolism [96,121,124].
CD39 and CD73 promote ATP hydrolysis to adenosine and shift the balance toward
immunosuppressive microenvironments. Being the rate-limiting enzyme in this process,
CD39 based therapeutics have the added advantage of ATP hydrolysis as well as promoting
sustained adenosine generation. However, CD39 is also a potent antithrombotic and
can cause bleeding if given systemically, but targeted-CD39 therapies promote localized,
sustained adenosine generation at the site of cellular injury without systemic bleeding
effects.
6. Targeted CD39 Therapeutics for Ischemic Stroke
This concept of targeted CD39 delivery is demonstrated by Hohmann et al. [125],
where they aimed to target CD39 to decrease ADP-induced platelet activation. Solu-
ble CD39 had previously been shown to reduce ADP concentration, preventing platelet
activation and recruitment [126]. The group aimed for a strong antithrombotic effect
via accumulation of CD39 through targeting with a single-chain antibody (scFv) against
the active conformation of GPIIb/IIIa found on activated platelets. Their compound,
αIIbβ3Targ-CD39, exhibited specific binding to activated platelets and successfully inhib-
ited the thrombosis of the carotid artery at a CD39 dose, approximately 10 times lower
compared to a non-targ-CD39, without prolonged tail-bleeding time, which has been the
main limiting factor in CD39 therapies [125].
This concept was further explored by our group; we showed that a novel construct of
recombinant soluble CD39 (rsol.CD39-PSGL) linked with a 20 amino-acid P-selectin tag
was able to protect against kidney IRI at a dose that did not perturb hemostasis. The mice
injected with the construct showed significantly less kidney damage compared to those
injected with the soluble CD39, and that a lower dose of targeted CD39 was needed as
opposed to soluble CD39 to confer protection, without prolonged tail-bleeding time [127].
The efficacy of targeted CD39 against thrombosis was tested when a novel construct
of dimeric GPVI-Fc was fused to CD39 (GPVI-CD39), aimed to increase platelet inhibitory
potential and to create a lesion-directed dual antiplatelet therapy with minimal bleeding
risks [128]. It was found that there was significant inhibition of ADP-induced platelet
aggregation as well as significantly delaying ferric chloride induced thrombosis, while not
increasing bleeding potential [128].
Therefore, targeting CD39 to either activated platelets of a thrombus or to an activated
endothelium is a potent antithrombotic, and can be delivered in systemic concentrations
that avoid the risk of bleeding, and is thus a potential therapeutic for vascular diseases.
7. Conclusions
Endothelial dysfunction in the brain is an important underlying pathology of ischemic
stroke and cerebral small vessel disease. It promotes oxidative stress, alters erythrocyte
deformability, and promotes platelet activation and thrombosis as well as adhesion and
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transmigration of leukocytes. Adenosine is an endogenous molecule that can attenuate
each of these pathological events. Accordingly, CD39 and CD39 therapies, that boost
local adenosine levels in the brain, are strong therapeutic candidates to treat endothelial
dysfunction underlying cerebrovascular diseases.
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